Patents by Inventor Liuhong Yun
Liuhong Yun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10889575Abstract: The invention belongs to the field of medicine and chemical industry and relates to a 4,4-diphenylpiperidine compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same and uses thereof. In particular, the invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, and to a pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof. In the present invention, the compound or pharmaceutically acceptable salt thereof and the pharmaceutical composition have significant activity in blocking an N-type calcium channel, and have good pharmacokinetic properties, can effectively relieve pain, and have a potential as a new medicament for prevention or treatment of pain, stroke, cerebral ischemia, alcohol addiction, alcoholism, kidney disease, addictive disorder caused by analgesic or tolerance disorder caused by analgesic.Type: GrantFiled: January 12, 2018Date of Patent: January 12, 2021Assignee: Academy of Military Medical SciencesInventors: Cheng Zhang, Haoshan Wang, Guoxing Dong, Ning Wu, Shuzhuo Zhang, Xiaomei Zhuang, Chong Pang, Juan Wang, Rifang Yang, Jianquan Zheng, Jin Li, Liuhong Yun
-
Publication number: 20190359604Abstract: The invention belongs to the field of medicine and chemical industry and relates to a 4,4-diphenylpiperidine compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same and uses thereof. In particular, the invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, and to a pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof. In the present invention, the compound or pharmaceutically acceptable salt thereof and the pharmaceutical composition have significant activity in blocking an N-type calcium channel, and have good pharmacokinetic properties, can effectively relieve pain, and have a potentialas a new medicament for prevention or treatment of pain, stroke, cerebral ischemia, alcohol addiction, alcoholism, kidney disease, addictive disorder caused by analgesic or tolerance disorder caused by analgesic.Type: ApplicationFiled: January 12, 2018Publication date: November 28, 2019Applicant: Academy of Military Medical SciencesInventors: Cheng Zhang, Haoshan WANG, Guoxing DONG, Ning WU, Shuzhuo ZHANG, Xiaomei ZHUANG, Chong PANG, Juan WANG, Rifang YANG, Jianquan ZHENG, Jin LI, Liuhong YUN
-
Patent number: 9227944Abstract: The present invention relates to a novel piperazine derivative represented by Formula I having an activity for regulating dopamine D3 receptor, stereoisomers thereof, pharmaceutically acceptable salts or solvates, and a pharmaceutical composition comprising the compound, a process for preparing the same, and use thereof in the prevention or treatment of a disease associated with central nervous system dysfunction, such as Parkinson's disease, schizophrenia, drug addiction and relapse, as well as kidney protection and immunoregulation, or as a tool for researching D3R function or diseases associated with D3R dysfunction.Type: GrantFiled: June 3, 2014Date of Patent: January 5, 2016Assignee: INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY SCIENCE P.L.A. CHINAInventors: Jin Li, Rifang Yang, Rui Song, Hui Zhu, Ning Wu, Liuhong Yun, Ruibin Su, Rusheng Zhao
-
Patent number: 8980887Abstract: Disclosed are 2-arylimidazo[1,2-a]pyridine-3-acetamide derivatives represented by formula I, their tautomer, racemate or optical isomer, their pharmaceutically acceptable salt, or their solvates, wherein R1, R2, R3 and R4 are defined as in the specification.Type: GrantFiled: June 9, 2011Date of Patent: March 17, 2015Assignees: Institute of Pharmacology, Toxicology Academy of Military Medical Sciences P.L.A., ChinaInventors: Rifang Yang, Yunfeng Li, Yongzhen Li, Nan Zhao, Liuhong Yun, Juanjuan Qin, Zhongyao Feng, Youzhi Zhang
-
Patent number: 8921563Abstract: Provided are N-[(4-hydroxypiperidin-4-yl)methyl]pyridin-2(1H)-one derivatives represented by formula I, stereoisomers, pharmaceutically acceptable salts or solvates thereof. The above compounds have the dual activities of 5-hydroxytryptamine 1A receptor ligand and selective serotonin reuptake inhibitor. The preparation methods of the above compounds, the uses of these compounds for the prevention or treatment of nervous system diseases related to 5-hydroxytryptamine system dysfunction and the pharmaceutical compositions containing these compounds are also provided.Type: GrantFiled: April 8, 2011Date of Patent: December 30, 2014Assignee: Institue of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A., ChinaInventors: Yunfeng Li, Rifang Yang, Youzhi Zhang, Yongzhen Li, Zengliang Jin, Peng Li, Li Yuan, Liuhong Yun, Nan Zhao, Cheng Zhang, Xiaodan Xu, Rusheng Zhao, Hongxia Chen, Rui Xue, Juanjuan Qin, Zhenzhen Wang, Jiazhi Yao
-
Publication number: 20140329831Abstract: The present invention relates to a novel piperazine derivative represented by Formula I having an activity for regulating dopamine D3 receptor, stereoisomers thereof, pharmaceutically acceptable salts or solvates, and a pharmaceutical composition comprising the compound, a process for preparing the same, and use thereof in the prevention or treatment of a disease associated with central nervous system dysfunction, such as Parkinson's disease, schizophrenia, drug addiction and relapse, as well as kidney protection and immunoregulation, or as a tool for researching D3R function or diseases associated with D3R dysfunction.Type: ApplicationFiled: June 3, 2014Publication date: November 6, 2014Inventors: Jin LI, Rifang Yang, Rui Song, Hui Zhu, Ning Wu, Liuhong Yun, Ruibin Su, Rusheng Zhao
-
Patent number: 8829001Abstract: The present invention relates to a novel piperazine derivative represented by Formula I having an activity for regulating dopamine D3 receptor, stereoisomers thereof, pharmaceutically acceptable salts or solvates, and a pharmaceutical composition comprising the compound, a process for preparing the same, and use thereof in the prevention or treatment of a disease associated with central nervous system dysfunction, such as Parkinson's disease, schizophrenia, drug addiction and relapse, as well as kidney protection and immunoregulation, or as a tool for researching D3R function or diseases associated with D3R dysfunction.Type: GrantFiled: September 28, 2009Date of Patent: September 9, 2014Assignee: The Institute of Pharmacology and Toxicology Academy of Military Medical Science P.L.A. ChinaInventors: Jin Li, Rifang Yang, Rui Song, Hui Zhu, Ning Wu, Liuhong Yun, Ruibin Su, Rusheng Zhao
-
Publication number: 20130231369Abstract: Provided are N-[(4-hydroxypiperidin-4-yl)methyl]pyridin-2(1H)-one derivatives represented by formula I, stereoisomers, pharmaceutically acceptable salts or solvates thereof. The above compounds have the dual activities of 5-hydroxytryptamine 1A receptor ligand and selective serotonin reuptake inhibitor. The preparation methods of the above compounds, the uses of these compounds for the prevention or treatment of nervous system diseases related to 5-hydroxytryptamine system dysfunction and the pharmaceutical compositions containing these compounds are also provided.Type: ApplicationFiled: April 8, 2011Publication date: September 5, 2013Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Yunfeng Li, Rifang Yang, Youzhi Zhang, Yongzhen Li, Zengliang Jin, Peng Li, Li Yuan, Liuhong Yun, Nan Zhao, Cheng Zhang, Xiaodan Xu, Rusheng Zhao, Hongxia Chen, Rui Xue, Juanjuan Qin, Zhenzhen Wang, Jiazhi Yao
-
Publication number: 20130203754Abstract: Disclosed are 2-arylimidazo[1,2-a]pyridine-3-acetamide derivatives represented by formula I, their tautomer, racemate or optical isomer, their pharmaceutically acceptable salt, or their solvates, wherein R1, R2, R3 and R4 are defined as in the specification.Type: ApplicationFiled: June 9, 2011Publication date: August 8, 2013Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Rifang Yang, Yunfeng Li, Yongzhen Li, Nan Zhao, Liuhong Yun, Juanjuan Qin, Zhongyao Feng, Youzhi Zhang
-
Publication number: 20110319423Abstract: The present invention relates to a novel piperazine derivative represented by Formula I having an activity for regulating dopamine D3 receptor, stereoisomers thereof, pharmaceutically acceptable salts or solvates, and a pharmaceutical composition comprising the compound, a process for preparing the same, and use thereof in the prevention or treatment of a disease associated with central nervous system dysfunction, such as Parkinson's disease, schizophrenia, drug addiction and relapse, as well as kidney protection and immunoregulation, or as a tool for researching D3R function or diseases associated with D3R dysfunction.Type: ApplicationFiled: September 28, 2009Publication date: December 29, 2011Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Science, P.L.AInventors: Jin Li, Rifang Yang, Rui Song, Hui Zhu, Ning Wu, Liuhong Yun, Ruibin Su, Rusheng Zhao
-
Patent number: 7560473Abstract: The present invention provides amine derivatives represented by formula I, its isomers, racemes or optical isomers, pharmaceutical salts thereof, its amides or esters, pharmaceutical compositions containing said compounds and the preparation methods thereof. The invention also relates to the use of the above mentioned compounds in the preparation of drugs for the prophylaxis or treatment of cardiovascular diseases, diabetes, bronchial and urinary smooth muscle spasm as well as ischemic and anoxic nerve injury. The above compounds can be used to treat hypertension, angina diaphragmatic, myocardial infarction, congestive heart failure, arrhythmia, diabetes, spasmodic bronchial diseases, spasmodic bladder or ureter diseases, and depression.Type: GrantFiled: January 21, 2002Date of Patent: July 14, 2009Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences, P.L.A.Inventors: Hai Wang, Liuhong Yun, Huasong Feng, Fulin Li, Xingchun Tang, Huamei He, Rifang Yang, Wenyu Cui, Qixiu Gao, Gang Hu, Rusheng Zhao, Wei Liu, Chaoliang Long, Lin Wang, Xinqiang Lu, Lijun Liu, Yuan Yan
-
Patent number: 7304057Abstract: This invention relates to substituted 6-membered N-Herterocyclic neurotrophic compounds of formula (I) or pharmaceutically acceptable salts or hydrates thereof, wherein R1, R2, X, Y, and Z are as defined in the description; their preparation methods, compositions comprising the same, and their use as inhibitors of FK560 binding proteases activity for treating and preventing neurodegenerative diseases and other nerve disorders associated with nerve injuries or other related diseasesType: GrantFiled: December 5, 2002Date of Patent: December 4, 2007Assignee: Institute of Pharmacology and Toxicology Accademy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Aihua Nie, Beifen Shen, Lili Wang, Wuhong Pei, Junhai Xiao, Songcheng Yang, Liuhong Yun, Hongying Liu, Cuiling Shu, Hongxia Wang, Zihe Rao
-
Patent number: 7262183Abstract: This invention relates to substituted 5-membered N-Herterocyclic neurotrophic compounds of formula (I) or pharmaceutically acceptable salts or hydrates thereof, wherein R1, R2, R3, R4, V, W, X, Y, and Z are as defined in the description; their preparation methods, compositions comprising the same, and their use as inhibitors of FK560 binding proteases (FKBPs) activity for treating and preventing neurodegenerative diseases and other nerve disorders associated with nerve injuries or other related diseases.Type: GrantFiled: December 5, 2002Date of Patent: August 28, 2007Assignees: Instititute of Pharmacology and Toxicology, Academy of Military Medical Sciences P.L.A.Inventors: Song Li, Liqin Zhao, Lili Wang, Beifen Shen, Liuhong Yun
-
Publication number: 20060094547Abstract: An integrated pulley-torsional damper assembly (1) comprises a hub (2) designed for being rigidly connected to a drive member (3), a pulley (4) connected to the hub (2) by means of a first ring (5) made of elastomeric material having the function of filter for the torsional oscillations, and an inertia ring (6), connected to the hub (2) by means of a second ring (7) made of elastomeric material, which defines with the inertia ring (6) a damping system. The first elastomeric ring is connected to the hub by mans of a coupling flange (25), which can be pack-tightened between an internal annular flange (10) of the hub and the drive member (3), the hub (2) comprising a first cylindrical wall (11) and a second cylindrical wall (12), which are coaxial with respect to one another and define between them an annular cavity (9) housing the first elastomeric ring (5), the external cylindrical wall (12) defining a support for the second elastomeric ring (7).Type: ApplicationFiled: July 10, 2003Publication date: May 4, 2006Inventors: Ouishou Xu, Lin Wang, Chaoyang Tong, Changjiang Guo, Qiujun Lu, Liuhong Yun, Lihua Dai, Mingtang Sun
-
Publication number: 20050171166Abstract: This invention relates to substituted 5-membered N-Herterocyclic neurotrophic compounds of formula (I) or pharmaceutically acceptable salts or hydrates thereof, wherein R1, R2, R3, R4, V, W, X, Y, and Z are as defined in the description; their preparation methods, compositions comprising the same, and their use as inhibitors of FK560 binding proteases (FKBPs) activity for treating and preventing neurodegenerative diseases and other nerve disorders associated with nerve injuries or other related diseases.Type: ApplicationFiled: December 5, 2002Publication date: August 4, 2005Inventors: Song Li, Liqin Zhao, Lili Wang, Beifen Shen, Liuhong Yun
-
Publication number: 20050130958Abstract: This invention relates to substituted 6-membered N-Herterocyclic neurotrophic compounds of formula (I) or pharmaceutically acceptable salts or hydrates thereof, wherein R1, R2, X, Y, and Z are as defined in the description; their preparation methods, compositions comprising the same, and their use as inhibitors of FK560 binding proteases activity for treating and preventing neurodegenerative diseases and other nerve disorders associated with nerve injuries or other related diseases.Type: ApplicationFiled: December 5, 2002Publication date: June 16, 2005Inventors: Song Li, Aihua Nie, Beifen Shen, Lili Wang, Wuhong Pei, Junhai Xiao, Songcheng Yang, Liuhong Yun, Hongying Liu, Cuiling Shu, Hongxia Wang, Zihe Rao
-
Publication number: 20040266822Abstract: The present invention provides amine derivatives represented by formula I, its isomers, racemes or optical isomers, pharmaceutical salts thereof, its amides or esters, pharmaceutical compositions containing said compounds and the preparation methods thereof. The invention also relates to the use of the above mentioned compounds in the preparation of drugs for the prophylaxis or treatment of cardiovascular diseases, diabetes, bronchial and urinary smooth muscle spasm as well as ischemic and anoxic nerve injury. The above compounds can be used to treat hypertension, angina diaphragmatic, myocardial infarction, congestive heart failure, arrhythmia, diabetes, spasmodic bronchial diseases, spasmodic bladder or ureter diseases, and depression.Type: ApplicationFiled: August 12, 2004Publication date: December 30, 2004Inventors: Hai Wang, Liuhong Yun, Huasong Feng, Fulin Li, Xingehun Tang, Huamei He, Rifang Yang, Wenyu Cui, Qixiu Gao, Gang Hu, Rusheng Zhao, Wei Liu, Chaoliang Long, Lin Wang, Xinqiang Lu, Lijun Liu, Yuan Yan
-
Patent number: 6028198Abstract: The present invention involves a pharmaceutical composition for preventing and treating motion sickness syndrome, the method of using it to treat motion sickness syndrome and the method for preparing phencynonate hydrochloride of .alpha.-configuration, the active component of the pharmaceutical composition. As compared with the known anti-motion sickness drugs, the pharmaceutical composition of the present invention showed higher efficacy and lower side effects. In addition, the pharmaceutical composition of the present invention can also be used for preventing and treating many symptoms of functional disorders of central and peripheral cholinergic system resulting from excessive central and peripheral acetyl choline.Type: GrantFiled: April 19, 1996Date of Patent: February 22, 2000Assignee: Institute of Pharmacology and Toxicology Academy of Military Sciences P.L.A.Inventors: Chuanhui Liu, Liuhong Yun, Guangling Wen, Fanzhong Zeng, Ruiqi Yu, Guihua Yu, Xiaoming Wang, Weixian Wang, Aiping Wang